Injecting preliminary discovery into patent infringement proceedings
Sovereign Hydroseal Pty Ltd v Steynberg  FCA 1084 An application for preliminary discovery of documents relating to the constituents of a ‘sealing composition’ and methods of using it to seal...
Sovereign Hydroseal Pty Ltd v Steynberg  FCA 1084 An application for preliminary discovery of documents relating to the constituents of...
Read More
Aristocrat hits the jackpot as electronic gaming machine found patentable
Aristocrat Technologies Australia Pty Limited v Commissioner of Patents FCA 778 Aristocrat Technologies Australia Pty Limited (ATA) appealed to the Federal Court from an Australian Patent Office decision that...
Aristocrat Technologies Australia Pty Limited v Commissioner of Patents FCA 778 Aristocrat Technologies Australia Pty Limited (ATA) appealed to...
Read More
Switching from Biologic to Biosimilar: Australia’s Unique Approach
Switching patients from an originator biologic (the reference product) to a biosimilar version has been a topic of keen interest in recent years, both in Australia and globally, as...
Switching patients from an originator biologic (the reference product) to a biosimilar version has been a topic of keen...
Read More
It is becoming clearer when computer-implemented methods are likely, or unlikely, to be deemed patentable subject matter in Australia – Encompass, Rokt and other recent decisions
During the past decade, the patent-eligibility of computer-implemented methods has been a particularly vexing focal point for Australian patent law and practice. With computer technologies now ubiquitous and relatively...
During the past decade, the patent-eligibility of computer-implemented methods has been a particularly vexing focal point for Australian patent...
Read More
TGA transparency reforms (part 2): Early publication of major innovator prescription medicine applications
In Part 1 of this series (available here), we examined the impact of the proposal by Australia’s Therapeutic Goods Administration (TGA) to provide early confidential notification to innovators of applications under evaluation...
In Part 1 of this series (available here), we examined the impact of the proposal by Australia’s Therapeutic Goods Administration (TGA) to...
Read More
TGA transparency reforms (part 1): Notification of generic and biosimilar medicines to impact pharmaceutical patent disputes in Australia
Regulatory changes recently approved by the Australian Government are likely to impact the way in which pharmaceutical patent litigation is conducted in Australia. The Therapeutic Goods Administration (TGA) is...
Regulatory changes recently approved by the Australian Government are likely to impact the way in which pharmaceutical patent litigation...
Read More
COVID-19: mRNA vaccines – a promising approach to vaccine development
The urgent need to develop an effective vaccine to provide individuals and populations worldwide with immunity against the COVID-19 disease caused by the novel coronavirus, SARS-CoV-2, has led several...
The urgent need to develop an effective vaccine to provide individuals and populations worldwide with immunity against the COVID-19...
Read More
Biosimilars in Australia
A ‘biosimilar medicine’ or ‘biosimilar’ is a highly similar, but not identical, version of an original biological medicine (‘reference medicine’) – a medicine comprised of large complex molecules derived...
A ‘biosimilar medicine’ or ‘biosimilar’ is a highly similar, but not identical, version of an original biological medicine (‘reference...
Read More

Contact our Expert Team

Contact Us
Contact Us